NO20071352L - Opioiddoseringsformer som har doseproporsjonal likevekts CAVE og AUC og mindre enn doseproporsjonal enkeltdose CMAX - Google Patents
Opioiddoseringsformer som har doseproporsjonal likevekts CAVE og AUC og mindre enn doseproporsjonal enkeltdose CMAXInfo
- Publication number
- NO20071352L NO20071352L NO20071352A NO20071352A NO20071352L NO 20071352 L NO20071352 L NO 20071352L NO 20071352 A NO20071352 A NO 20071352A NO 20071352 A NO20071352 A NO 20071352A NO 20071352 L NO20071352 L NO 20071352L
- Authority
- NO
- Norway
- Prior art keywords
- dosage forms
- dose
- dosage
- cave
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Det tilveiebringes et antall doseringsformer omfattende en første doseringsform og en andre doseringsform, hver omfattende et terapeutisk middel som et opioid, der doseringsstyrken for den andre doseringsform er større enn den til den første doseringsform, og der stabiltilstands Cave og stabiltilstands AUC for de første og andre doseringsformer er doseproporsjonale, og enkeltdose C.max,, for den andre doseringsform er mindre enn minimumsnivået for doseproporsjonalitet i forhold til den første doseringsform. Den foreliggende oppfinnelse angår også fremgangsmåter for administrering av slike doseringsformer til en pasient så vel som sett som omfatter slike doseringsformer og instruksjoner for administrering av doseringsformene til en pasient. Det antas at doseringsformene og metodene i følge oppfinnelsen vil føre til forbedret sikkerhet og pasientaksept.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60635404P | 2004-09-01 | 2004-09-01 | |
PCT/US2005/030892 WO2006028830A2 (en) | 2004-09-01 | 2005-08-30 | Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20071352L true NO20071352L (no) | 2007-05-30 |
Family
ID=35759199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20071352A NO20071352L (no) | 2004-09-01 | 2007-03-13 | Opioiddoseringsformer som har doseproporsjonal likevekts CAVE og AUC og mindre enn doseproporsjonal enkeltdose CMAX |
Country Status (15)
Country | Link |
---|---|
US (2) | US9326959B2 (no) |
EP (1) | EP1786404A2 (no) |
JP (1) | JP4997109B2 (no) |
KR (2) | KR20080046751A (no) |
CN (1) | CN101010072A (no) |
AU (1) | AU2005282784B2 (no) |
BR (1) | BRPI0515600A (no) |
CA (1) | CA2578540A1 (no) |
EA (1) | EA010627B1 (no) |
IL (1) | IL181600A0 (no) |
MX (1) | MX2007002135A (no) |
NO (1) | NO20071352L (no) |
UA (1) | UA85750C2 (no) |
WO (1) | WO2006028830A2 (no) |
ZA (1) | ZA200700620B (no) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU230828B1 (en) | 1999-10-29 | 2018-08-28 | Euro Celtique Sa | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
HU230875B1 (hu) | 2000-10-30 | 2018-11-29 | Euro-Celtique S.A. | Szabályozott hatóanyag-leadású hidrokodon készítmények |
CA2665841C (en) | 2006-10-09 | 2016-04-05 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
CA2905541C (en) | 2008-01-09 | 2020-02-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
JP2011511782A (ja) | 2008-02-12 | 2011-04-14 | アボット・ラボラトリーズ | 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途 |
JP5607550B2 (ja) * | 2008-03-11 | 2014-10-15 | ディポメド,インコーポレイティド | 非オピオイド鎮痛剤及びオピオイド鎮痛剤の組合せを含む胃保持性持続放出剤形 |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US20100068275A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Personalizable dosage form |
US20100069821A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-sites final dosage form |
US20100069887A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multiple chamber ex vivo adjustable-release final dosage form |
US20100068278A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liablity Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-associations |
US20100068235A1 (en) * | 2008-09-16 | 2010-03-18 | Searete LLC, a limited liability corporation of Deleware | Individualizable dosage form |
US20100068254A1 (en) * | 2008-09-16 | 2010-03-18 | Mahalaxmi Gita Bangera | Modifying a medicament availability state of a final dosage form |
US20100068233A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Modifiable dosage form |
CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
WO2011026125A2 (en) * | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
US10322120B2 (en) | 2012-07-31 | 2019-06-18 | Persion Pharmaceuticals Llc | Treating pain in patients with hepatic impairment |
US20140161879A1 (en) * | 2012-07-31 | 2014-06-12 | Zogenix, Inc. | Treating pain in patients with hepatic impairment |
US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988004922A1 (en) | 1986-12-25 | 1988-07-14 | Teysan Pharmaceuticals Co., Ltd. | Slowly soluble granule and persistently effective composite granule prepared therefrom |
US4971805A (en) * | 1987-12-23 | 1990-11-20 | Teysan Pharmaceuticals Co., Ltd. | Slow-releasing granules and long acting mixed granules comprising the same |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5656295A (en) * | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5273760A (en) * | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5324351A (en) * | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US20020006438A1 (en) * | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
DE69722191T2 (de) * | 1996-03-08 | 2004-04-01 | Nycomed Danmark Aps | Dosiszusammensetzung mit modifizierter freigabe aus vielen einzelkomponenten |
DE19630035A1 (de) | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
FR2772615B1 (fr) | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
US6806294B2 (en) * | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
HU230828B1 (en) | 1999-10-29 | 2018-08-28 | Euro Celtique Sa | Controlled release hydrocodone formulations |
BR0008059A (pt) | 1999-12-08 | 2002-03-26 | Pharmacia Corp | Composições de valdecoxib |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
US6874926B2 (en) * | 2001-11-26 | 2005-04-05 | Nokia Corporation | Illumination system for an electronic device |
DK200200669A (da) * | 2002-05-02 | 2003-11-03 | Schur Packaging Systems As | Fremgangsmåde og apparat til fyldning af indhold i folieposer samt emballageemne til anvendelse ved fremgangsmåden og i apparatet |
-
2005
- 2005-08-30 WO PCT/US2005/030892 patent/WO2006028830A2/en active Application Filing
- 2005-08-30 CA CA002578540A patent/CA2578540A1/en not_active Abandoned
- 2005-08-30 JP JP2007530288A patent/JP4997109B2/ja not_active Expired - Fee Related
- 2005-08-30 BR BRPI0515600-9A patent/BRPI0515600A/pt not_active Application Discontinuation
- 2005-08-30 EA EA200700500A patent/EA010627B1/ru not_active IP Right Cessation
- 2005-08-30 MX MX2007002135A patent/MX2007002135A/es active IP Right Grant
- 2005-08-30 KR KR1020087011539A patent/KR20080046751A/ko not_active Application Discontinuation
- 2005-08-30 EP EP05793064A patent/EP1786404A2/en not_active Withdrawn
- 2005-08-30 KR KR1020077007466A patent/KR20070048272A/ko not_active Application Discontinuation
- 2005-08-30 US US11/660,988 patent/US9326959B2/en active Active
- 2005-08-30 AU AU2005282784A patent/AU2005282784B2/en active Active
- 2005-08-30 CN CNA2005800289928A patent/CN101010072A/zh active Pending
- 2005-08-30 UA UAA200703642A patent/UA85750C2/uk unknown
-
2007
- 2007-01-22 ZA ZA200700620A patent/ZA200700620B/en unknown
- 2007-02-27 IL IL181600A patent/IL181600A0/en unknown
- 2007-03-13 NO NO20071352A patent/NO20071352L/no not_active Application Discontinuation
-
2014
- 2014-03-07 US US14/201,040 patent/US9034377B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2008511657A (ja) | 2008-04-17 |
JP4997109B2 (ja) | 2012-08-08 |
EA200700500A1 (ru) | 2007-08-31 |
EP1786404A2 (en) | 2007-05-23 |
AU2005282784A1 (en) | 2006-03-16 |
WO2006028830A2 (en) | 2006-03-16 |
CN101010072A (zh) | 2007-08-01 |
ZA200700620B (en) | 2008-04-30 |
IL181600A0 (en) | 2007-07-04 |
US20080132532A1 (en) | 2008-06-05 |
UA85750C2 (uk) | 2009-02-25 |
US9034377B2 (en) | 2015-05-19 |
BRPI0515600A (pt) | 2008-07-29 |
AU2005282784B2 (en) | 2008-06-19 |
MX2007002135A (es) | 2007-04-02 |
US20140187572A1 (en) | 2014-07-03 |
US9326959B2 (en) | 2016-05-03 |
WO2006028830A3 (en) | 2006-05-26 |
KR20080046751A (ko) | 2008-05-27 |
KR20070048272A (ko) | 2007-05-08 |
CA2578540A1 (en) | 2006-03-16 |
EA010627B1 (ru) | 2008-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20071352L (no) | Opioiddoseringsformer som har doseproporsjonal likevekts CAVE og AUC og mindre enn doseproporsjonal enkeltdose CMAX | |
Jing et al. | Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review | |
CY1111595T1 (el) | Τροποποιηση της θεραπειας με πιρφενιδονη για ασθενεις με μη φυσιολογικη ηπατικη λειτουργια | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
MX2018011349A (es) | Uso de masitinib para el tratamiento de una subpoblacion de pacientes con esclerosis lateral amiotrofica. | |
UY28945A1 (es) | Derivados de pirrolopiridina | |
NO20064964L (no) | Behandling av svekket respiratorisk funksjon | |
DE602005009176D1 (de) | Behandlung von t-zellen-lymphom mittels 10-propargyl-10-deazaaminopterin | |
JP2017528483A5 (no) | ||
ECSP045501A (es) | Moduladores de receptores nucleares de hormonas esteroideas triciclicos | |
FR2878161B1 (fr) | Forme medicamenteuse orale, solide et concue pour eviter le mesusage | |
NO20072931L (no) | Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva | |
NO20081863L (no) | Forhindring og behandling av gastrointestinal og blaerelidelse assosiert med kemoterapi eller stralingsterapi ved bruk av aktiv vitamin D forbindelse | |
AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
MX2009011900A (es) | Curacion de herida diabetica. | |
NO20073813L (no) | Kladribinregime for behandling av multippel sklerose | |
CY1110369T1 (el) | Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη | |
MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
MX2021013942A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton. | |
DK1656131T3 (da) | Anvendelse af betain til behandling claudicatio intermittens | |
MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
Pešić et al. | Molecular Mechanism and Clinical Relevance of Ketamine as Rapid‐Acting Antidepressant | |
Bernstein et al. | Efficacy of omalizumab in patients with chronic idiopathic/spontaneous urticaria with different background therapy: post hoc analysis of Asteria I, Asteria II, and Glacial studies | |
HUP0303468A2 (hu) | Egy vagy több shogaol alkalmazása afrodiziákumként | |
Saini et al. | Whole blood histamine concentration response to omalizumab in patients with chronic idiopathic/spontaneous urticaria: post hoc analysis of ASTERIA I, ASTERIA II and GLACIAL studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: EURO-CELTIQUE SA, LU |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |